These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 15193382

  • 1. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2004 Jun 30; 22(20):2566-77. PubMed ID: 15193382
    [Abstract] [Full Text] [Related]

  • 2. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.
    J Med Virol; 2001 Sep 30; 65(1):178-84. PubMed ID: 11505461
    [Abstract] [Full Text] [Related]

  • 3. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G, Greenbaum E, Zakay-Rones Z.
    Isr Med Assoc J; 2006 Mar 30; 8(3):155-8. PubMed ID: 16599048
    [Abstract] [Full Text] [Related]

  • 4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 5. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 02; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 7. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 8. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.
    Vaccine; 2006 Jan 16; 24(3):254-62. PubMed ID: 16129526
    [Abstract] [Full Text] [Related]

  • 9. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.
    Vaccine; 2012 Jan 05; 30(2):466-74. PubMed ID: 22051136
    [Abstract] [Full Text] [Related]

  • 10. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, Schlesinger M, Levy R, Zakay-Rones Z, Friedman G.
    J Med Virol; 2000 May 05; 61(1):100-6. PubMed ID: 10745240
    [Abstract] [Full Text] [Related]

  • 11. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, Levy R, Friedman G, Zakay-Rones Z.
    Vaccine; 2003 Mar 07; 21(11-12):1180-6. PubMed ID: 12559796
    [Abstract] [Full Text] [Related]

  • 12. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN.
    J Infect Dis; 2004 Jul 01; 190(1):11-9. PubMed ID: 15195238
    [Abstract] [Full Text] [Related]

  • 13. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A, van Riet E, Ito R, Ikeda K, Senchi K, Suzuki T, Tamura SI, Asanuma H, Odagiri T, Tashiro M, Kurata T, Multihartina P, Setiawaty V, Pangesti KNA, Hasegawa H.
    Microbiol Immunol; 2020 Apr 01; 64(4):313-325. PubMed ID: 31957054
    [Abstract] [Full Text] [Related]

  • 14. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2006 Jul 01; 78(7):954-63. PubMed ID: 16721854
    [Abstract] [Full Text] [Related]

  • 15. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
    Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D.
    PLoS One; 2016 Jul 01; 11(12):e0163089. PubMed ID: 28005959
    [Abstract] [Full Text] [Related]

  • 16. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 18. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB.
    J Infect Dis; 2001 Jan 15; 183(2):329-332. PubMed ID: 11110645
    [Abstract] [Full Text] [Related]

  • 19. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
    Bizanov G, Janakova L, Knapstad SE, Karlstad T, Bakke H, Haugen IL, Haugan A, Samdal HH, Haneberg B.
    Scand J Immunol; 2005 Jun 15; 61(6):503-10. PubMed ID: 15963044
    [Abstract] [Full Text] [Related]

  • 20. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine.
    Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2002 Jan 15; 20(7-8):1232-9. PubMed ID: 11803086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.